U.S. Markets close in 3 hrs 28 mins

Seattle Genetics, Inc. (SGEN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.6532-1.90 (-3.35%)
As of 12:32PM EDT. Market open.
People also watch
IMGNBMRNINCYALNYCLDX
  • Echelon results are out. No 90% or greather but 82% without lung issue (long term terrible from personal knowledge) is still very good. Market reaction is same as when Adcetris received initial FDA approval. CC is either 8:30 this AM (Forbes) or 5:30 this PM (AP)
    Talking about snatching defeat from the jaws of victory.
    Kool
  • Whomever is buying now is going to make a lot of dough in a couple of days.
    Kool
  • New adcetris data in GVHD. "BV is tolerable and has activity in steroid-refractory acute GVHD and merits further
    investigation. " Big market.

    http://www.bloodjournal.org/content/early/2017/05/04/blood-2017-03-772210

  • Hey Satnam, bio sector is ticking up along with SGEN. Better cover your short and cut your losses before you lose your house.
  • LOAD UP SOME OF IGXT MAJOR BREAKOUT IMMINENT ...
    IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • I bought a fresh batch of sgen at around 55. 💵🤑💵
  • Man... SAtnam is hillarious. Never seen such a desperate short before to post every 10 seconds claiming this stock is going to drop 82% LOL.
  • Posted in $ATNM conversation
    Very good news for $ATNM - drug candidate from $SGEN failed. This was competing drug for AML - Iomab-A. Their drug used same antibody CD-33. But they used a toxin to destroy cancer cell. $ATNM used radioactive particle, which has very little toxic affect on patients.

    $ATNM now has a clear field in the AML arena.
  • No getting around it - the failure of Cascade and the suspension of CD-33A investigations represent serious setbacks, though of course the rest of the SGEN pipeline remains robust and promising. It would be helpful if SGEN had conducted a conference call today to offer additional context and to soothe the market, but management remains tone deaf when it comes to public relations and crisis management. Consequently, the waters will be more choppy this week than they need be.
  • Maybe the CD33 trial cancellation is no so bad. CD33 is expressed on both cancerous and normal myeloid cells. The normal CD33 cells play an important part in the immune system so killing them off along with the cancerous cells doesn't produce the best outcome. On the other hand, SGEN has another candidate SGN-CD123A and they claim the CD123 is only expressed on malignant myeloid cells. In other words CD123 is a much better target then CD33.
  • Tripped 10% breakers at open.
    What would it have done if the trial failed? Do we have a great management team or what?
    Could not get up early to have a CC to prevent this savagery from happening.
  • Sell Long and Go Short to Cover Losses
  • SELL Short Now While Management is trying to manipulate
  • It will break 52 week low today for Sure
  • SGEN will see $10 tomorrow
  • It will Open $5 tomorrow after news
  • Sell before too late guys, this junk is going under $2
  • Closing $20 today
  • Suicidal to stay long now
  • All Funds will Dump now after this bad news